{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:35:29Z","timestamp":1792193729341,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n          <jats:p>There is an increasing use of medical management for gynecologic cancers given the rise in neoadjuvant therapies, delayed childbearing, and use of assisted reproductive technology. Chemotherapy, albeit broadly used in most gynecologic cancers, lacks long term data with respect to its associated gonadotoxicity and potential adverse pregnancy outcomes. Immunotherapy and other targeted therapies that have demonstrated promising responses in other tumor types are increasingly being studied in gynecologic malignancies. These therapies may offer opportunities for enhanced treatment response in an effort to minimize more toxic, invasive, or surgical management approaches that could have significant negative implications on fertility. Given that some of these therapies do not represent the standard of care and currently only exist in the experimental setting, detailed counseling and careful selection of patients for fertility sparing treatment remains critical. It is reasonable for patients with early stage, low-risk endometrial cancers to attempt conservative management while establishing clear treatment objectives. Early involvement of fertility specialists is necessary in order to optimize these patients\u2019 pregnancy goals. An emphasis on lifestyle changes and in particular weight loss should also be discussed with these patients. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervix cancer patients with low-risk, small tumors shows promising results that suggest this can be a safe treatment option. Patients with advanced stage disease of any primary tumor or aggressive histology such as in many cases of ovarian cancer are not appropriate candidates for prioritization of fertility sparing treatment options. Ongoing and future studies will help to better identify appropriate patients and maximize medical management options in early-stage gynecologic cancers.<\/jats:p>","DOI":"10.1007\/s11864-025-01299-4","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:12:35Z","timestamp":1739963555000},"page":"157-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fertility Sparing Medical Management Options in Gynecologic Cancers"],"prefix":"10.1007","volume":"26","author":[{"given":"Ana","family":"Kouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle P.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"48","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.15585\/mmwr.mm6748a1","volume":"67","author":"SJ Henley","year":"2018","unstructured":"Henley SJ. Uterine Cancer Incidence and Mortality- United Staets, 1999\u20132016. MMWR Morb Mortal Wkly Rep. 2018;67(48):1333\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/cncr.34479","volume":"128","author":"KA Cronin","year":"2022","unstructured":"Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022;128(24):4251\u201384.","journal-title":"Cancer"},{"issue":"39","key":"1299_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.15585\/mmwr.mm6639e1","volume":"66","author":"CB Steele","year":"2017","unstructured":"Steele CB, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, et al. Vital signs: trends in incidence of cancers associated with overweight and obesity - United States, 2005\u20132014. MMWR Morb Mortal Wkly Rep. 2017;66(39):1052\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"1299_CR4","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.3390\/jcm10204784","volume":"10","author":"U Leone Roberti Maggiore","year":"2021","unstructured":"Leone Roberti Maggiore U, Khamisy-Farah R, Bragazzi NL, Bogani G, Martinelli F, Lopez S, et al. Fertility-sparing treatment of patients with endometrial cancer: a review of the literature. J Clin Med. 2021;10(20):4784.","journal-title":"J Clin Med"},{"issue":"1","key":"1299_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12\u201339.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"21","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine neoplasms, version 1.2023, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(2):181\u2013209.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"1299_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","volume":"125","author":"CC Gunderson","year":"2012","unstructured":"Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477\u201382.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1299_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00404-014-3417-z","volume":"291","author":"C Ohyagi-Hara","year":"2015","unstructured":"Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015;291(1):151\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"19","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","volume":"25","author":"K Ushijima","year":"2007","unstructured":"Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25(19):2798\u2013803.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1299_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/IGC.0000000000000723","volume":"26","author":"Y Qin","year":"2016","unstructured":"Qin Y, Yu Z, Yang J, Cao D, Yu M, Wang Y, et al. Oral Progestin Treatment for early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2016;26(6):1081\u201391.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"547.e1","DOI":"10.1016\/j.ajog.2010.07.037","volume":"203","author":"ID Gallos","year":"2010","unstructured":"Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1299_CR12","doi-asserted-by":"publisher","first-page":"266e12","DOI":"10.1016\/j.ajog.2012.08.011","volume":"207","author":"ID Gallos","year":"2012","unstructured":"Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266e12.","journal-title":"Am J Obstet Gynecol"},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"100732","DOI":"10.1016\/j.gore.2021.100732","volume":"36","author":"M Dore","year":"2021","unstructured":"Dore M, Filoche S, Danielson K, Henry C. Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response? Gynecol Oncol Rep. 2021;36:100732.","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajog.2024.07.018","volume":"231","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Ferris JS, Chen L, Dioun S, Usseglio J, Matsuo K, et al. Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024;231(6):599.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1299_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","volume":"125","author":"J Baker","year":"2012","unstructured":"Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263\u201370.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","volume":"131","author":"N Pal","year":"2018","unstructured":"Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109\u201316.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/AOG.0b013e31828d6186","volume":"121","author":"JL Hubbs","year":"2013","unstructured":"Hubbs JL, Saig RM, Abaid LN, Bae-Jump VL, Gehrig PA. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol. 2013;121(6):1172\u201380.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajog.2020.08.032","volume":"224","author":"SN Westin","year":"2021","unstructured":"Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstetr Gynecol. 2021;224(2):191-e1.","journal-title":"Am J Obstetr Gynecol"},{"key":"1299_CR19","doi-asserted-by":"publisher","first-page":"1391546","DOI":"10.3389\/fonc.2024.1391546","volume":"14","author":"J Cui","year":"2024","unstructured":"Cui J, Zhao YC, She LZ, Wang TJ. Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a systematic review and network meta-analysis. Front Oncol. 2024;14:1391546.","journal-title":"Front Oncol"},{"issue":"5","key":"1299_CR20","first-page":"5412","volume":"13","author":"F Fang","year":"2021","unstructured":"Fang F, Xu H, Wu L, Hu L, Liu Y, Li Y, et al. LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia. Am J Transl Res. 2021;13(5):5412\u20139.","journal-title":"Am J Transl Res"},{"issue":"3","key":"1299_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","volume":"132","author":"GF Fleming","year":"2014","unstructured":"Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132(3):585\u201392.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1299_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/IGC.0000000000001008","volume":"27","author":"H Zhou","year":"2017","unstructured":"Zhou H, Cao D, Yang J, Shen K, Lang J. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer. 2017;27(6):1178\u201382.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1299_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s13063-024-08414-0","volume":"25","author":"Q Liu","year":"2024","unstructured":"Liu Q, Zhou H, Yu M, Cao D, Yang J. GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. Trials. 2024;25(1):578.","journal-title":"Trials"},{"issue":"1","key":"1299_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/jcm11010196","volume":"11","author":"G Aimagambetova","year":"2021","unstructured":"Aimagambetova G, Terzic S, Lagana AS, Bapayeva G, la Fleur P, Terzic M. Contemporary fertility-sparing management options of early stage endometrioid endometrial cancer in young nulliparous patients. J Clin Med. 2021;11(1):196.","journal-title":"J Clin Med."},{"issue":"2","key":"1299_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/annonc\/mdv539","volume":"27","author":"A Mitsuhashi","year":"2016","unstructured":"Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27(2):262\u20136.","journal-title":"Ann Oncol"},{"issue":"11","key":"1299_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.6004\/jnccn.2019.0053","volume":"17","author":"NR Abu-Rustum","year":"2019","unstructured":"Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. gestational trophoblastic neoplasia, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(11):1374\u201391.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"1299_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/AOG.0000000000004240","volume":"137","author":"JT Soper","year":"2021","unstructured":"Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021;137(2):355\u201370.","journal-title":"Obstet Gynecol"},{"key":"1299_CR28","doi-asserted-by":"publisher","unstructured":"Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, et al (2017) Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 9(9):CD007289. https:\/\/doi.org\/10.1002\/14651858.CD007289.pub3","DOI":"10.1002\/14651858.CD007289.pub3"},{"issue":"7","key":"1299_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","volume":"29","author":"RJ Osborne","year":"2011","unstructured":"Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29(7):825\u201331.","journal-title":"J Clin Oncol"},{"key":"1299_CR30","doi-asserted-by":"publisher","unstructured":"Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;2016(6):CD007102. https:\/\/doi.org\/10.1002\/14651858.CD007102.pub4","DOI":"10.1002\/14651858.CD007102.pub4"},{"issue":"1","key":"1299_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12885-021-08849-7","volume":"21","author":"J Hao","year":"2021","unstructured":"Hao J, Zhou W, Zhang M, Yu H, Zhang T, An R, et al. Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies. BMC Cancer. 2021;21(1):1122.","journal-title":"BMC Cancer"},{"issue":"2","key":"1299_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ygyno.2020.05.013","volume":"158","author":"JC Schink","year":"2020","unstructured":"Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG\/GOG 275. Gynecol Oncol. 2020;158(2):354\u201360.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1299_CR33","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/ijgc-2023-004292","volume":"33","author":"W Xue","year":"2023","unstructured":"Xue W, Cang W, Zhao J, Feng F, Wan X, Ren T, et al. Effect of actinomycin D on ovarian reserve in low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2023;33(8):1222\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1299_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/ijgc-2020-001784","volume":"31","author":"U Joneborg","year":"2021","unstructured":"Joneborg U, Coopmans L, van Trommel N, Seckl M, Lok CAR. Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Cancer. 2021;31(3):399\u2013411.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"1299_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1590\/1806-9282.62.09.837","volume":"62","author":"MT Garcia","year":"1992","unstructured":"Garcia MT, Lin LH, Fushida K, Francisco RP, Zugaib M. Pregnancy outcomes after chemotherapy for trophoblastic neoplasia. Rev Assoc Med Bras. 1992;62(9):837\u201342.","journal-title":"Rev Assoc Med Bras"},{"key":"1299_CR36","doi-asserted-by":"crossref","unstructured":"Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1(Suppl 1):86\u201393.","DOI":"10.1002\/ijgo.13877"},{"issue":"5","key":"1299_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/1471-0528.17374","volume":"130","author":"BB Albright","year":"2023","unstructured":"Albright BB, Ellett T, Knochenhauer HE, Goins EC, Monuszko KA, Kaplan SJ, et al. Treatments and outcomes in high-risk gestational trophoblastic neoplasia: A systematic review and meta-analysis. BJOG. 2023;130(5):443\u201353.","journal-title":"BJOG"},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bpobgyn.2021.01.005","volume":"74","author":"A Braga","year":"2021","unstructured":"Braga A, Elias KM, Horowitz NS, Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance\/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021;74:81\u201396.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"1299_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0090-8258(02)00071-9","volume":"88","author":"H Matsui","year":"2003","unstructured":"Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Seki K, et al. Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. Gynecol Oncol. 2003;88(2):104\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1299_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/ijgc-2019-000604","volume":"29","author":"A Tranoulis","year":"2019","unstructured":"Tranoulis A, Georgiou D, Sayasneh A, Tidy J. Gestational trophoblastic neoplasia: a meta-analysis evaluating reproductive and obstetrical outcomes after administration of chemotherapy. Int J Gynecol Cancer. 2019;29(6):1021\u201331.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"1299_CR41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","volume":"40","author":"S Inaguma","year":"2016","unstructured":"Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): Analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol. 2016;40(8):1133\u201342.","journal-title":"Am J Surg Pathol"},{"issue":"27","key":"1299_CR42","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1200\/JCO.20.00803","volume":"38","author":"B You","year":"2020","unstructured":"You B, Bolze PA, Lotz JP, Massardier J, Gladieff L, Joly F, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. J Clin Oncol. 2020;38(27):3129\u201337.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1299_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3322\/caac.21628","volume":"70","author":"ETH Fontham","year":"2020","unstructured":"Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321\u201346.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1299_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","volume":"17","author":"WJ Koh","year":"2019","unstructured":"Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64\u201384.","journal-title":"J Natl Compr Canc Netw."},{"issue":"21","key":"1299_CR45","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.3390\/jcm10214825","volume":"10","author":"F Zaccarini","year":"2021","unstructured":"Zaccarini F, Sanson C, Maulard A, Scherier S, Leary A, Pautier P, et al. Cervical cancer and fertility-sparing treatment. J Clin Med. 2021;10(21):4825.","journal-title":"J Clin Med"},{"issue":"3","key":"1299_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ygyno.2019.09.025","volume":"155","author":"KGG van Kol","year":"2019","unstructured":"van Kol KGG, Vergeldt TFM, Bekkers RLM. Abdominal radical trachelectomy versus chemotherapy followed by vaginal radical trachelectomy in stage 1B2 (FIGO 2018) cervical cancer A systematic review on fertility and recurrence rates. Gynecol Oncol. 2019;155(3):515\u201321.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"1299_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/ijgc-2020-001765","volume":"31","author":"J Burbano","year":"2021","unstructured":"Burbano J, Heredia F, Sanabria D, Ardila EG, Viveros-Carreno D, Rodriguez J. Neoadjuvant chemotherapy prior to fertility-sparing surgery in cervical tumors larger than 2 cm: a systematic review on fertility and oncologic outcomes. Int J Gynecol Cancer. 2021;31(3):387\u201398.","journal-title":"Int J Gynecol Cancer"},{"key":"1299_CR48","doi-asserted-by":"crossref","unstructured":"D\u2019Amato A, Riemma G, Agrifoglio V, Chiantera V, Lagana AS, Mikus M, et al. Reproductive outcomes in young women with early-stage cervical cancer greater than 2 cm undergoing fertility-sparing treatment: a systematic review. Medicina (Kaunas) 60(4)608","DOI":"10.3390\/medicina60040608"},{"issue":"3","key":"1299_CR49","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ygyno.2021.06.006","volume":"162","author":"NI Gwacham","year":"2021","unstructured":"Gwacham NI, McKenzie ND, Fitzgerald ER, Ahmad S, Holloway RW. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2\u20134 cm; emerging data and future perspectives. Gynecol Oncol. 2021;162(3):809\u201315.","journal-title":"Gynecol Oncol"},{"issue":"32","key":"1299_CR50","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1200\/JCO.22.02852","volume":"41","author":"GG Kenter","year":"2023","unstructured":"Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, et al. Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994. J Clin Oncol. 2023;41(32):5035\u201343.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1299_CR51","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.21873\/anticanres.14485","volume":"40","author":"A Gadducci","year":"2020","unstructured":"Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020;40(9):4819\u201328.","journal-title":"Anticancer Res"},{"issue":"12","key":"1299_CR52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(23)00467-9","volume":"24","author":"TN Schuurman","year":"2023","unstructured":"Schuurman TN, Schaafsma M, To KH, Verhoef VMJ, Sikorska K, Siebers AG, et al. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study. Lancet Oncol. 2023;24(12):1349\u201358.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1299_CR53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3322\/caac.21557","volume":"69","author":"RA Smith","year":"2019","unstructured":"Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: A review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184\u2013210.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1299_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"JB Trimbos","year":"2003","unstructured":"Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase iii trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1299_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","volume":"102","author":"J Bell","year":"2006","unstructured":"Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2006;102(3):432\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1299_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1299_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/GRF.0b013e318248050d","volume":"55","author":"LG Seamon","year":"2012","unstructured":"Seamon LG, Richardson DL, Copeland LJ. Evolution of the gynecologic oncology group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55(1):131\u201355.","journal-title":"Clin Obstet Gynecol"},{"issue":"18","key":"1299_CR58","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.3390\/jcm10184235","volume":"10","author":"G Canlorbe","year":"2021","unstructured":"Canlorbe G, Chabbert-Buffet N, Uzan C. Fertility-sparing surgery for ovarian cancer. J Clin Med. 2021;10(18):4235.","journal-title":"J Clin Med"},{"issue":"1","key":"1299_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/gyno.2002.6805","volume":"87","author":"JM Schilder","year":"2002","unstructured":"Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87(1):1\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1299_CR60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/annonc\/mds241","volume":"24","author":"R Fruscio","year":"2013","unstructured":"Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol. 2013;24(1):138\u201344.","journal-title":"Ann Oncol"},{"issue":"13","key":"1299_CR61","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice P, Gouy S, Leary A. Mucinous Ovarian Carcinoma. N Engl J Med. 2019;380(13):1256\u201366.","journal-title":"N Engl J Med"},{"key":"1299_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcsup.2020.02.001","volume":"15","author":"I Romero","year":"2020","unstructured":"Romero I, Leskela S, Mies BP, Velasco AP, Palacios J. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. EJC Suppl. 2020;15:1\u201315.","journal-title":"EJC Suppl"},{"issue":"1","key":"1299_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst. 2019;111(1):60\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1299_CR64","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1200\/GO.21.00085","volume":"7","author":"VD Vanderpuye","year":"2021","unstructured":"Vanderpuye VD, Clemenceau JRV, Temin S, Aziz Z, Burke WM, Cevallos NL, et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2021;7:1032\u201366.","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"1299_CR65","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ygyno.2019.05.009","volume":"154","author":"D Nasioudis","year":"2019","unstructured":"Nasioudis D, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Ko EM, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol. 2019;154(2):302\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1299_CR66","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/AOG.0000000000003579","volume":"134","author":"KC Kurnit","year":"2019","unstructured":"Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, et al. Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma. Obstet Gynecol. 2019;134(6):1253\u20139.","journal-title":"Obstet Gynecol"},{"key":"1299_CR67","doi-asserted-by":"crossref","unstructured":"Anthon C, Vidal A, Recker H, Piccand E, Pape J, Weidlinger S, et al (2021) Long-term effects on gonadal function after treatment of colorectal cancer: a systematic review and meta-analysis. Cancers (Basel) 16(23):4005","DOI":"10.3390\/cancers16234005"},{"issue":"3","key":"1299_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clcc.2013.04.007","volume":"12","author":"A Cercek","year":"2013","unstructured":"Cercek A, Siegel CL, Capanu M, Reidy-Lagunes D, Saltz LB. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin Colorectal Cancer. 2013;12(3):163\u20137.","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"1299_CR69","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","volume":"33","author":"RN Grisham","year":"2023","unstructured":"Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023;33(9):1331\u201344.","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"1299_CR70","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017;35(10):1103\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1299_CR71","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cancers12051336","volume":"12","author":"A Gadducci","year":"2020","unstructured":"Gadducci A, Cosio S. Therapeutic approach to low-grade serous ovarian carcinoma: state of art and perspectives of clinical research. Cancers (Basel). 2020;12(5):1336.","journal-title":"Cancers (Basel)."},{"issue":"24","key":"1299_CR72","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.7150\/jca.26674","volume":"9","author":"N Thomakos","year":"2018","unstructured":"Thomakos N, Malakasis A, Machairiotis N, Zarogoulidis P, Rodolakis A. Fertility Sparing Management in Non-Epithelial Ovarian Cancer Which Patients, What Procedure and What Outcome? J Cancer. 2018;9(24):4659\u201364.","journal-title":"J Cancer"},{"issue":"3","key":"1299_CR73","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejca.2014.12.004","volume":"51","author":"T Satoh","year":"2015","unstructured":"Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, et al. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015;51(3):340\u201351.","journal-title":"Eur J Cancer"},{"issue":"9 Suppl 3","key":"1299_CR74","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1097\/IGC.0000000000000249","volume":"24","author":"I Ray-Coquard","year":"2014","unstructured":"Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S42\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1299_CR75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/gyno.1998.5304","volume":"72","author":"HD Homesley","year":"1999","unstructured":"Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;72(2):131\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1299_CR76","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0029-7844(95)00491-2","volume":"87","author":"DM Gershenson","year":"1996","unstructured":"Gershenson DM, Morris M, Burke TW, Levenback C, Matthews CM, Wharton JT. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol. 1996;87(4):527\u201331.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1299_CR77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygyno.2005.01.011","volume":"97","author":"J Brown","year":"2005","unstructured":"Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97(2):489\u201396.","journal-title":"Gynecol Oncol"},{"key":"1299_CR78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ygyno.2024.09.002","volume":"190","author":"J Brown","year":"2024","unstructured":"Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, et al. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology\/gynecologic oncology group study14. Gynecol Oncol. 2024;190:283\u201390.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1299_CR79","doi-asserted-by":"publisher","first-page":"267.e5","DOI":"10.1016\/j.fertnstert.2009.07.1007","volume":"93","author":"CL Dicken","year":"2010","unstructured":"Dicken CL, Lieman HJ, Dayal AK, Mutyala S, Einstein MH. A multidisciplinary approach to fertility-sparing therapy for a rare vulvar tumor. Fertil Steril. 2010;93(1):267.e5.","journal-title":"Fertil Steril"},{"issue":"6","key":"1299_CR80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dmz027","volume":"25","author":"N Spears","year":"2019","unstructured":"Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673\u201393.","journal-title":"Hum Reprod Update"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01299-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:38:06Z","timestamp":1742351886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01299-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}